Overall market sentiment has been down on Calliditas Therapeutics Adr Rep 2 Ord Shs (CALT) stock lately. CALT receives a Bearish rating from InvestorsObserver's Stock Sentiment Indicator.
What is Stock Sentiment?
Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends.
Price action is generally the best indicator of sentiment. For a stock to go up, investors must feel good about it. Similarly, a stock that is in a downtrend must be out of favor.
InvestorsObserver’s Sentiment Indicator considers price action and recent trends in volume. Increasing volumes often mean that a trend is strengthening, while decreasing volumes can signal that a reversal could come soon.
The options market is another place to get signals about sentiment. Since options allow investors to place bets on the price of a stock, we consider the ratio of calls and puts for stocks where options are available.
What's Happening With CALT Stock Today?
Calliditas Therapeutics Adr Rep 2 Ord Shs (CALT) stock is trading at $27.10 as of 1:21 PM on Thursday, Apr 15, a loss of -$0.12, or -0.44% from the previous closing price of $27.22. Volume today is elevated. So far 112,351 shares have traded compared to average volume of 28,938 shares. The stock has traded between $27.02 and $27.32 so far today.
More About Calliditas Therapeutics Adr Rep 2 Ord Shs
Calliditas Therapeutics AB operates as a specialty pharmaceutical company in Sweden. The company is engaged in the provision of pharmaceutical products for patients with niche indications. It is focused on the development and commercialization of the product candidate Nefecon intended for the treatment of patients with the inflammatory renal disease IgA nephropathy, a disease that causes chronic inflammation of the kidneys.